PriceTargets.com logo

Genfit - GNFT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 222.58%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.41 As of 04/25/2024 12:42 PM ET
▼ -0.08 (-2.29%)

This chart shows the closing price for GNFT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Genfit Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GNFT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GNFT

Analyst Price Target is $11.00
▲ +222.58% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Genfit in the last 3 months. The average price target is $11.00, with a high forecast of $11.00 and a low forecast of $11.00. The average price target represents a 222.58% upside from the last price of $3.41.

This chart shows the closing price for GNFT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Genfit. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00Low
12/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00Low
9/21/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00Low
7/3/2023HC WainwrightBoost Target$9.00 ➝ $11.00Low
4/17/2023HC WainwrightBoost TargetBuy$8.00 ➝ $9.00Low
4/14/2023SVB LeerinkReiterated RatingOutperformLow
3/17/2023Bank of AmericaLower Target$5.00 ➝ $4.00Low
4/11/2022SVB LeerinkLower TargetOutperform$15.00 ➝ $10.00High
12/20/2021HC WainwrightUpgradeNeutral ➝ Buy$8.00High
12/17/2021Oddo BhfUpgradeBuyHigh
9/30/2021HC WainwrightLower TargetNeutral$8.00 ➝ $7.00Low
4/5/2021SVB LeerinkLower TargetOutperform$20.00 ➝ $15.00Medium
2/12/2021Bryan, Garnier & CoUpgradeNeutral ➝ BuyLow
11/16/2020HC WainwrightReiterated RatingHoldLow
9/29/2020HC WainwrightReiterated RatingHold$8.00Medium
8/5/2020HC WainwrightReiterated RatingHold$8.00Low
7/23/2020HC WainwrightLower TargetNeutral$11.00 ➝ $8.00High
7/23/2020Stifel NicolausUpgradeHold ➝ BuyHigh
6/25/2020Bank of AmericaInitiated CoverageUnderperform$7.00High
5/22/2020B. RileyBoost TargetBuy$134.00 ➝ $174.00Low
5/13/2020Bryan, Garnier & CoDowngradeBuy ➝ NeutralMedium
5/13/2020Kepler Capital MarketsDowngradeBuy ➝ ReduceHigh
5/12/2020B. RileyDowngradeBuy ➝ Neutral$9.00High
5/12/2020Roth CapitalReiterated RatingBuyHigh
5/12/2020Oddo BhfDowngradeBuy ➝ ReduceHigh
5/12/2020SVB LeerinkLower TargetOutperform$50.00 ➝ $20.00High
5/12/2020HC WainwrightDowngradeBuy ➝ Neutral$46.00 ➝ $11.00High
5/12/2020BarclaysDowngradeOverweight ➝ Equal Weight$55.00 ➝ $14.00High
4/9/2020B. RileyReiterated RatingBuy$34.00N/A
4/9/2020HC WainwrightLower TargetPositive ➝ Buy$58.00 ➝ $46.00Medium
4/1/2020B. RileyReiterated RatingBuy$34.00High
3/13/2020B. RileyLower TargetBuy$43.00 ➝ $34.00High
2/21/2020B. RileyReiterated RatingBuy$43.00High
1/2/2020SVB LeerinkReiterated RatingOutperformLow
11/26/2019B. RileyReiterated RatingBuy$43.00Low
10/31/2019HC WainwrightLower TargetBuy$72.00 ➝ $58.00High
10/29/2019B. RileyLower TargetBuy$52.00 ➝ $43.00High
9/3/2019HC WainwrightSet TargetBuy$72.00Low
6/25/2019Stifel NicolausInitiated CoverageHold ➝ HoldHigh
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Genfit logo
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
Read More

Today's Range

Now: $3.41
Low: $3.40
High: $3.56

50 Day Range

MA: $3.59
Low: $3.41
High: $3.90

52 Week Range

Now: $3.41
Low: $2.89
High: $4.75

Volume

12,335 shs

Average Volume

14,876 shs

Market Capitalization

$169.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Genfit?

The following Wall Street research analysts have issued reports on Genfit in the last twelve months: HC Wainwright.
View the latest analyst ratings for GNFT.

What is the current price target for Genfit?

1 Wall Street analysts have set twelve-month price targets for Genfit in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 222.6%. HC Wainwright has the highest price target set, predicting GNFT will reach $11.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $11.00 for Genfit in the next year.
View the latest price targets for GNFT.

What is the current consensus analyst rating for Genfit?

Genfit currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GNFT will outperform the market and that investors should add to their positions of Genfit.
View the latest ratings for GNFT.

What other companies compete with Genfit?

Other companies that are similar to Genfit include Compugen, Candel Therapeutics, Kodiak Sciences, 10X Capital Venture Acquisition Corp. III and Scilex. Learn More about companies similar to Genfit.

How do I contact Genfit's investor relations team?

Genfit's physical mailing address is PARC 885 AVENUE EUGENE AVINEE, LOOS I0, 59120. The company's listed phone number is (332) 016-4000 and its investor relations email address is [email protected]. The official website for Genfit is www.genfit.com. Learn More about contacing Genfit investor relations.